Question special
Trainee ST 4-8

I'd be interested to know how you, as the authors, would summarise the strengths and weaknesses of your study? And what questions you think still need to be answered for the clinical impact of Nirsevimab to be fully understood (besides Nirsevimab vs. Palivuzimab given the previous reply)?